Research Article

Effective Mobilization of Very Small Embryonic-Like Stem Cells and Hematopoietic Stem/Progenitor Cells but Not Endothelial Progenitor Cells by Follicle-Stimulating Hormone Therapy

Monika Zbucka-Kretowska, 1 Andrzej Eljaszewicz, 2 Danuta Lipinska, 2,3 Kamil Grubczak, 2 Malgorzata Rusak, 4 Grzegorz Mrugacz, 5 Milena Dabrowska, 4 Mariusz Z. Ratajczak, 6,7 and Marcin Moniuszko 2,8

1 Department of Reproduction and Gynecological Endocrinology, Medical University of Bialystok, 15-276 Bialystok, Poland
2 Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, 15-269 Bialystok, Poland
3 Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276 Bialystok, Poland
4 Department of Hematological Diagnostics, Medical University of Bialystok, 15-276 Bialystok, Poland
5 Center for Reproductive Medicine Bociak, 15-267 Bialystok, Poland
6 Stem Cell Institute at James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA
7 Department of Regenerative Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland
8 Department of Allergology and Internal Medicine, Medical University of Bialystok, 15-276 Bialystok, Poland

Correspondence should be addressed to Marcin Moniuszko; marcin.moniuszko@umb.edu.pl

Received 1 May 2015; Accepted 8 June 2015

Academic Editor: Irma Virant-Klun

Copyright © 2016 Monika Zbucka-Kretowska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Recently, murine hematopoietic progenitor stem cells (HSCs) and very small embryonic-like stem cells (VSELs) were demonstrated to express receptors for sex hormones including follicle-stimulating hormone (FSH). This raised the question of whether FSH therapy at clinically applied doses can mobilize stem/progenitor cells in humans. Here we assessed frequencies of VSELs (referred to as Lin-CD235a-CD45-CD133+ cells), HSPCs (referred to as Lin-CD235a-CD45-CD133+ cells), and endothelial progenitor cells (EPCs, identified as CD34+CD144+, CD34+CD133+, and CD34+CD309+CD133+ cells) in fifteen female patients subjected to the FSH therapy. We demonstrated that FSH therapy resulted in statistically significant enhancement in peripheral blood (PB) number of both VSELs and HSPCs. In contrast, the pattern of responses of EPCs delineated by different cell phenotypes was not uniform and we did not observe any significant changes in EPC numbers following hormone therapy. Our data indicate that FSH therapy mobilizes VSELs and HSPCs into peripheral blood that on one hand supports their developmental origin from germ lineage, and on the other hand FSH can become a promising candidate tool for mobilizing HSCs and stem cells with VSEL phenotype in clinical settings.

1. Introduction

Maintenance of appropriate size and composition of both stem cell and progenitor cell pool is tightly regulated by continuous responding to surrounding and long-range orchestrating signals. Interestingly, sex hormones appeared lastly as important regulators of hematopoietic stem/progenitor cells (HSPCs) proliferation [1]. Recently, Nakada and colleagues revealed that hematopoietic stem cells (HSCs) expressed high levels of estrogen receptor and the administration of estradiol increased HSC cell division and self-renewal [2]. In support of this notion, murine HSPCs along with very small embryonic-like stem cells (VSELs) were also recently demonstrated to express receptors for pituitary-derived sex hormones, namely, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) [3]. In concert with this finding, murine HSPCs and VSELs following either in vitro or in vivo FSH and LH stimulation presented with high proliferative
response as evidenced by BrdU incorporation. In the light of above mentioned observations, it is tempting to hypothesize the existence of developmental link between HSCs and VSELs and primordial germ cells (PGCs) that are naturally responsive to sex hormones [4, 5].

To date, however, it remained unknown whether the fact that stem cells are susceptible to signaling mediated by sex hormones can be used for mobilization of these cells in clinical settings. Moreover, based on the currently available scarce data, it is difficult to speculate if therapies using sex hormones will exert only fate of primordial stem cells and HSCs or rather would exert their actions toward all progenitor cell populations. Therefore, in the current study, we wished to investigate the effects of FSH therapy at clinically applied doses on mobilization of HSCs and VSELs as well as populations of endothelial progenitor cells (EPCs). In this study, EPCs were chosen as an example of easily identifiable, highly differentiated, and relatively numerous progenitor cell populations that account for endothelial repair and thus largely contribute to maintenance of appropriate vasculature [6–8]. On the other hand, quantification of decreased numbers of EPCs was found to improve prognostication of cardiovascular diseases (CVD) [9–11]. Thus, the search for therapeutic approaches aimed at efficient mobilization of functional EPCs is continuously warranted.

Here we tested in human model the actions of widely accepted regimens of FSH treatment with regard to three stem/progenitor cell subsets at different developmental hierarchy and differentiation level, namely, VSELs, HSCs, and EPCs. Moreover, given the previous reports indicating the crucial role of stroma derived factor-1 (SDF-1) for mobilization of stem cells [12–14], we set out to analyze whether any actions of clinically applied gonadotropins could affect not only stem cells and progenitor cells but also mediators regulating their migratory pathways.

2. Material and Methods

2.1. Patients and FSH Stimulation. For the purpose of the study we recruited fifteen women aged 32.9 ± 3.9 years (range: 27–39 years) who were prepared for in vitro fertilization and underwent controlled FSH ovarian stimulation. FSH stimulation has been initiated on 3rd day of menstrual cycle and FSH dose was adjusted based on patient age, ovarian reserve, and previous response to FSH stimulation (if performed). Only two patients received stimulation based on combination of FSH and LH. EDTA-anticoagulated peripheral blood was collected twice: before FSH ovarian stimulation (or in five cases within first days of such stimulation) and at the end of FSH stimulation (days 7–11). Mean daily dose of FSH (either Gonal F, Merck Serono, or Puregon, Schering, or, in two patients, Menopur, Ferring) was 194.4 IU. Detailed characteristics of hormonal status of analyzed patients are presented in Table 1.

All patients’ samples were collected upon the approval of Ethics Committee of the Medical University of Bialystok.

| Studied parameter                              | Mean  | SD    | Minimum | Maximum |
|-----------------------------------------------|-------|-------|---------|---------|
| Age (years)                                   | 32.9  | 3.9   | 27      | 39      |
| Duration of stimulation (days)                | 8.8   | 1.1   | 8       | 11      |
| Mean daily dose of FSH (IU)                   | 194.4 | 43.8  | 120     | 262.5   |
| Number of mature follicles after FSH stimulation | 10.9  | 3.4   | 5       | 16      |
| Estradiol at 7th day (pg/mL)                  | 1153  | 405   | 540     | 1684    |
| Progesterone at 7th day (ng/mL)               | 0.5   | 0.15  | 0.25    | 0.67    |
| LH at 7th day (mIU/mL)                        | 1.1   | 0.67  | 0.31    | 2.33    |
| Estradiol at the last day (pg/mL)             | 2314  | 1367  | 1367    | 3294    |
| Progesterone at the last day (ng/mL)          | 0.8   | 0.33  | 0.32    | 1.52    |
| LH at the last day (mIU/mL)                   | 1.7   | 0.85  | 0.72    | 2.97    |
Table 2: Detailed characteristics of monoclonal antibodies used in the study.

| Name                              | Clone  | Isotype | Format | Additional information                                                                 | Manufacturer          |
|-----------------------------------|--------|---------|--------|----------------------------------------------------------------------------------------|------------------------|
| Mouse anti-human anti-CD34        | 8G12   | IgG1    | FITC   | This antibody binds to 105–120 kDa single-chain transmembrane glycoprotein, IVD         | Becton Dickinson       |
| Anti-human lineage cocktail 2 (lin 2) |        |         |        |                                                                                         |                        |
| Mouse anti-human anti-CD3         | SK7    | IgG1    | FITC   | This antibody binds to epsilon chain of the CD3 antigen, IVD                             | Becton Dickinson       |
| Mouse anti-human anti-CD19        | SJ25C1 | IgG1    |        | This antibody recognizes a 90 kDa antigen, IVD                                          | Becton Dickinson       |
| Mouse anti-human anti-CD20        | L27    | IgG1    |        | This antibody binds to phosphoprotein with a molecular weight of 35 or 37 kilodaltons (kDa), depending on the degree of phosphorylation, IVD | Becton Dickinson       |
| Mouse anti-human anti-CD14        | M₆P9   | IgG2b   |        | This antibody reacts with a 53–55 kDa glycosylphosphatidylinositol- (GPI-) anchored and single chain glycoprotein, IVD | Becton Dickinson       |
| Mouse anti-human anti-CD56        | NCAM16.2 | IgG2b   |        | This antibody recognizes a heavily glycosylated 140 kDa isoform of NCAM, a member of the immunoglobulin (Ig) superfamily, IVD | Becton Dickinson       |
| Mouse anti-human anti-CD235a      | GA-R2  | IgG2b   | FITC   | This antibody binds to glycoporin A, a sialoglycoprotein present on human red blood cells (RBC) and erythroid precursor cells | Becton Dickinson       |
| Mouse anti-human anti-CD45        | HI30   | IgG1    | PE     | This antibody binds to 190, 190, 205, and 220 kDa protein isoforms, RUO                  | Becton Dickinson       |
| Mouse anti-human anti-CD144       | 55-7H1 | IgG1    | PE     | This antibody reacts with calcium-independent epitope on cadherin 5, RUO                | Becton Dickinson       |
| Mouse anti-human anti-CD309       | 89106  | IgG1    | PE     | This antibody reacts with CD309 (vascular endothelial growth factor receptor-2 (VEGFR-2)) | Becton Dickinson       |
| Mouse anti-human anti-CD133       | AC133  | IgG1    | APC    | This antibody reacts with epitope 1 of CD133, RUO                                       | Miltenyi Biotec        |

IVD: this clone is used for *in vitro* diagnostics; RUO: suitable for research use only.

between 7.81 and 500 pg/mL. The samples were analyzed with automated light absorbance reader (LEDETEC 96 system). Results were calculated by MicroWin 2000 software.

2.4. Statistics. Statistical analysis was carried out using GraphPad Prism 6 (GraphPad software). Wilcoxon test was used. The differences were considered statistically significant at $p < 0.05$. The results are presented as medians (interquartile range).

3. Results

First, we analyzed the effects of FSH administration on the frequencies of circulating HSCs (Figure 3(a)). We found that FSH treatment resulted in statistically significant increase in Lin⁻CD133⁺CD45⁻ VSEL levels (Figure 3(b)). Following FSH therapy, VSEL numbers increased from 4 cells (3–11.5) to 34 cells (16.5–57) per 170 μL of whole blood ($p = 0.0057$).

Next, we set out to investigate the influence of FSH administration on the frequencies of entire population of CD34⁺ cells and the population of EPCs delineated by such phenotypes as CD34⁺CD144⁺, CD34⁺CD133⁺, and CD34⁺CD133⁺CD309⁺ cells. Notably, we did not observe any significant changes in the numbers of single CD34⁺ cells following FSH administration (Figure 4(a)). Similarly, we did not demonstrate any significant changes in numbers of EPCs identified as CD34⁺CD144⁺ cells (Figure 4(b)), CD34⁺CD133⁺ cells (Figure 4(c)), and CD34⁺CD133⁺CD309⁺ cells (Figure 4(d)).

Finally, we wished to investigate whether FSH administration affected serum levels of SDF-1, one of crucial mobilizing factors for VSELs and HSCs (Figure 5). However, we did not find any significant change in SDF-1 concentrations upon completion of FSH administration ($p > 0.05$).
Figure 1: Representative FACS plots demonstrating gating strategy for HSC and VSELs. First, 2–4 μm size events were gated based on a forward and side scatter (FSC/SSC) dot plot (a). Then the 2–4 μm gate was visualized on sample data using a FSC/SSC dot plot (b). Next, 2–4 μm events were displayed on histogram plot (black peak, FMO control; grey peak identifies positive staining) and Lin−CD235a− events were gated (c). Finally, FMO control was used to set the HSC and VSELs gate and exclude the background noise (d). Next, HSCs were defined as Lin−CD235a−CD45−CD133+ cells (upper gate) and VSELs were referred to as Lin−CD235a−CD45−CD133+ cells (e).
Figure 2: Representative FACS plots demonstrating the gating strategy for CD34+ cells and EPCs. PBMCs were gated based on forward and side scatter (FSC/SSC) plot (b). CD34+ cells were gated on CD34/SSC plot (c). CD34+CD144+ cells (upper right quadrant, Q2) were gated based on CD34/CD144 dot plot (d). FMO control was used to set the gates (a). In order to determine CD34+CD144+CD309+ cell numbers, the PBMC events were displayed on the basis of FMO control sample (e) and gates were set to exclude the random noise. Next, the gates were visualized on CD34/CD133 plot (f) and CD34+CD133+ cells were gated (upper right quadrant, Q2). Finally, CD34+CD133+CD309+ cells subsets were gated on histogram plot (g) (black peak, control; grey peak, positive staining).
4. Discussion

Here we demonstrated that administration of pituitary-derived sex hormones at clinically applied doses allowed for efficient mobilization of frequencies of VSELs and HSCs but not endothelial progenitor cells. These findings build a platform for developing novel sex-hormone-based therapeutic strategies aimed at enhancement of either VSELs or HSC numbers in conditions that would require efficient mobilization of these cell subsets.

Notably, it was shown that the links between gonadotropin hormones and stem cells may extend far beyond the effects exerted on VSELs and HSCs. Tadokoro and colleagues showed that FSH was one of crucial regulators...
after significant effects of gonadotropin therapy on the levels of SDF-1 could not be achieved in the setting of the current study. If enrollment of male patients subjected to therapy with FSH stems cell populations size are related to ovaries would require the question of how effects of gonadotropin hormones on numbers in chemoablated female mice [21]. Nevertheless, colleagues showed that PMSG (FSH analog) increased VSELs not on ovarian epithelial cells [20]. Similarly, Sriraman and FSH receptors were expressed only on ovarian stem cells but to their direct effects on bone marrow-derived stem cells or rather on mobilization of stem cells localized in ovaries. On the other hand, both possibilities do not have to be mutually exclusive. Previously, it was demonstrated that stem cells found in ovaries have the phenotype of VSELs and they can give rise to more differentiated ovarian GCS [17, 18]. This was confirmed by later studies by Parte and colleagues who demonstrated that VSELs and GSCs were present in ovary surface epithelium (OSE) [19]. In this study, FSH treatment resulted in prominent proliferation of stem cell-harboring OSE and release of functional stem cells from ovaries. Moreover, Patel and colleagues found that FSH treatment resulted in increased clonal expansion of ovary-associated stem cells (both VSELs and ovarian GCSs), while FSH receptors were expressed only on ovarian stem cells but not on ovarian epithelial cells [20]. Similarly, Sriraman and colleagues showed that PMSG (FSH analog) increased VSEL numbers in chemoablated female mice [21]. Nevertheless, the question of how effects of gonadotropin hormones on stem cell population size are related to ovaries would require enrollment of male patients subjected to therapy with FSH and/or LH, the condition that due to ethical reasons certainly could not be achieved in the settings of the current study.

Notably, in our study, we did not demonstrate any significant effects of gonadotropin therapy on the levels of SDF-1. Our findings also bring about an interesting perspective for understanding relationships between stem and progenitor cells and elevated levels of FSH and LH that are detected at elderly age. In the light of our data, it is tempting to hypothesize that enhanced FSH and LH levels in elderly individuals could represent the mechanism of enhancing otherwise diminished hematopoiesis and decreased stem cell numbers. Similarly, this observation was previously documented in mouse model wherein the numbers of VSELs were shown to be highest in young subjects and decreased with age [25].

Given these data, FSH and LH therapy could become an attractive and easily available tool enabling mobilization of stem cells in regenerative medicine. However, given the broad spectrum of the effects exerted by sex hormones, the safety of such approach would need to be examined in further clinical studies performed in different groups of patients including males. One has to keep in mind that FSH and LH were found to be involved in the growth of certain tumors. As an example, Ji and colleagues found significantly higher levels of mRNA encoding receptor for FSH (FSHR) in invasive ovarian tumors compared to low malignant tumors and normal OSE [26]. Similarly, it was reported that overexpression of FSHR in OSE cells led to an increase in expression of proteins involved in ovarian cancer development such as EGFR, c-myc, and HER2/neu. Thus any therapeutic strategies aimed at enhancement of the size of stem/progenitor cell pool by the use of gonadotropin-based therapies would need to be carefully investigated in terms of clinical safety.

Altogether, our data support recent findings on the role of FSH in the biology of VSELs and HSCs that were reported by our group in mouse model [4]. Thus, these data support a concept of a developmental link between germ line, VSELs, and hematopoiesis [4, 5]. Finally, we demonstrated here for the first time that mobilization of stem cells with VSELs phenotype and HSPCs can be achieved by the use of widely available therapeutic regimens based on pituitary-derived sex hormones.

**Conflict of Interests**

The University of Louisville is the owner of patents on VSELs and some areas of VSEL technology, which are licensed to Neostem Inc., New York. None of the authors have any stock in Neostem Inc., New York, or any other biotechnological stem cell company.
Authors’ Contribution
Monika Zbucka-Kretowska, Andrzej Eljaszewicz, and Danuta Lipinska equally contributed to the work.

Acknowledgments
The study was supported by funds of Leading National Research Center (KNOW) of Medical University of Bialystok. The authors wish to thank students of Scientific Society of Medical University of Bialystok for help in delivering blood samples.

References
[1] D. Gancz and L. Gilboa, "Hormonal control of stem cell systems," Annual Review of Cell and Developmental Biology, vol. 29, pp. 137–162, 2013.
[2] D. Nakada, H. Oguro, B. P. Levi et al., "Oestrogen increases hematopoietic stem-cell self-renewal in females and during pregnancy," Nature, vol. 505, no. 7484, pp. 555–558, 2014.
[3] K. Mierzewska, S. Borkowska, E. Suszynska et al., "Hematopoietic stem/progenitor cells express several functional sex hormone receptors—novel evidence for a potential developmental link between hematopoiesis and primordial germ cells," Stem Cells and Development, vol. 24, no. 8, pp. 927–937, 2015.
[4] M. Z. Ratajczak, K. Marycz, A. Poniewierska-Baran, K. Fiedorowicz, M. Zbucka-Kretowska, and M. Moniuszko, "Very small embryonic-like stem cells as a novel developmental concept and the hierarchy of the stem cell compartment," Advances in Medical Sciences, vol. 59, no. 2, pp. 273–280, 2014.
[5] M. L. Scaldaferreri, F. G. Klinger, D. Farini et al., "Hematopoietic activity in putative mouse primordial germ cell populations," Mechanisms of Development, vol. 136, pp. 53–63, 2015.
[6] M. Rusak, U. Radzikowska, B. Glowinska-Olszewska et al., "Endothelial progenitor cell levels in juvenile idiopathic arthritis patients; effects of anti-inflammatory therapies," Pediatric Rheumatology, vol. 13, no. 1, article 6, 2015.
[7] A. Y. Khakoo and T. Finkel, "Endothelial progenitor cells," Annual Review of Medicine, vol. 56, pp. 79–101, 2005.
[8] S. M. Goerke, J. Obermeyer, J. Plaha, G. B. Stark, and G. Finkenzeller, "Endothelial progenitor cells from peripheral blood support bone regeneration by provoking an angiogenic response," Microvascular Research, vol. 98, pp. 40–47, 2015.
[9] B. Glowinska-Olszewska, M. Moniuszko, A. Hryniewicz et al., "Relationship between circulating endothelial progenitor cells and endothelial dysfunction in children with type 1 diabetes: a novel paradigm of early atherosclerosis in high-risk young patients," European Journal of Endocrinology, vol. 168, no. 2, pp. 153–161, 2013.
[10] J. R. Lavoie and D. J. Stewart, "Genetically modified endothelial progenitor cells in the therapy of cardiovascular disease and pulmonary hypertension," Current Vascular Pharmacology, vol. 10, no. 3, pp. 289–299, 2012.
[11] S. Sen, S. P. McDonald, P. T. H. Coates, and C. S. Bonder, "Endothelial progenitor cells: novel biomarker and promising cell therapy for cardiovascular disease," Clinical Science, vol. 120, no. 7, pp. 263–283, 2011.
[12] M. Z. Ratajczak, C. H. Kim, A. Abdel-Latif et al., "A novel perspective on stem cell homing and mobilization: review on bioactive lipids as potent chemoattractants and cationic peptides as underappreciated modulators of responsiveness to SDF-1 gradients," Leukemia, vol. 26, no. 1, pp. 63–72, 2012.
[13] M. Kucia, R. Reca, K. Miekus et al., "Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis," Stem Cells, vol. 23, no. 7, pp. 879–894, 2005.
[14] M. Kucia, J. Ratajczak, R. Reca, A. Janowska-Wieczorek, and M. Z. Ratajczak, "Tissue-specific muscle, neural and liver stem/progenitor cells reside in the bone marrow, respond to an SDF-1 gradient and are mobilized into peripheral blood during stress and tissue injury," Blood Cells, Molecules, and Diseases, vol. 32, no. 1, pp. 52–57, 2004.
[15] Y. Tedokoro, K. Yomogida, H. Ohta, A. Tohda, and Y. Nishimune, "Homeostatic regulation of germinal stem cell proliferation by the GDNF/FSH pathway," Mechanisms of Development, vol. 113, no. 1, pp. 29–39, 2002.
[16] I. L. Tourkova, M. R. Witt, L. Li et al., "Follicle stimulating hormone receptor in mesenchymal stem cells integrates effects of glycoprotein reproductive hormones," Annals of the New York Academy of Sciences, vol. 1335, no. 1, pp. 100–109, 2015.
[17] S. Parte, D. Bhartiya, J. Telang et al., "Detection, characterization, and spontaneous differentiation in vitro of very small embryonic-like putative stem cells in adult mammalian ovary," Stem Cells and Development, vol. 20, no. 8, pp. 1451–1464, 2011.
[18] I. Virant-Klun, N. Zech, P. Rozman et al., "Putative stem cells with an embryonic character isolated from the ovarian surface epithelium of women with no naturally present follicles and oocytes," Differentiation, vol. 76, no. 8, pp. 843–856, 2008.
[19] S. Parte, D. Bhartiya, D. D. Manjramkar, A. Chauhan, and A. Joshi, "Stimulation of ovarian stem cells by follicle stimulating hormone and basic fibroblast growth factor during cortical tissue culture," Journal of Ovarian Research, vol. 6, article 20, 2013.
[20] H. Patel, D. Bhartiya, S. Parte, P. Gunjal, S. Yedurkar, and M. Bhatt, "Follicle stimulating hormone modulates ovarian stem cells through alternately spliced receptor variant FSH-R3," Journal of Ovarian Research, vol. 6, article 52, 2013.
[21] K. Sriraman, D. Bhartiya, S. Anand, and S. Bhutda, "Mouse ovarian very small embryonic-like stem cells resist chemotherapy and retain ability to initiate oocyte-specific differentiation," Reproductive Sciences, 2015.
[22] A. Garolla, R. D’Inca, D. Cechchin et al., "Reduced endothelial progenitor cell number and function in inflammatory bowel disease: a possible link to the pathogenesis," American Journal of Gastroenterology, vol. 104, no. 10, pp. 2500–2507, 2009.
[23] C. Foresta, L. de Toni, R. Selice, A. Garolla, and A. di Mambro, "Increased osteocalcin-positive endothelial progenitor cells in hypogonadal male patients," Journal of Endocrinological Investigation, vol. 33, no. 7, pp. 439–442, 2010.
[24] A. Siraj, V. Desestret, M. Antoine et al., "Expression of follicle-stimulating hormone receptor by the vascular endothelium in tumor metastases," BMC Cancer, vol. 13, article 246, 2013.
[25] M. Kucia, R. Reca, F. R. Campbell et al., "A population of very small embryonic-like (VSEL) CXCR4+ SSEA-1+Oct-4+ stem cells identified in adult bone marrow," Leukemia, vol. 20, no. 5, pp. 857–869, 2006.
[26] Q. Ji, P. I. Liu, P. K. Chen, and C. Aoyama, "Follicle stimulating hormone-induced growth promotion and gene expression profiles on ovarian surface epithelial cells," International Journal of Cancer, vol. 112, no. 5, pp. 803–814, 2004.